Effective December 1, 2013, Harvard Pilgrim has established a medical policy on the use of injectable bulking agents to treat fecal incontinence in adults. Solesta is currently the only injectable fecal bulking agent available on the market. Because current medical literature does not support the long-term effectiveness and medical necessity of fecal bulking agents, Harvard Pilgrim will continue to deny coverage. This policy is consistent with the practices of other health plans in the region, as well. For more information, please review Harvard Pilgrim's Bulking Agents for Treatment of Fecal Incontinence Medical Policy.